Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 04:49:34 GMT 2023
by
admin
on
Sat Dec 16 04:49:34 GMT 2023
|
Protein Type | MONOCLONAL ANTIBODY |
Protein Sub Type | IGG4 |
Sequence Origin | HUMANIZED MOUSE |
Sequence Type | COMPLETE |
Record UNII |
DPT0O3T46P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
705319
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
502415
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
570816
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
578717
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
576917
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
511715
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
548216
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
WHO-ATC |
L01XC18
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
481715
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
605417
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
495415
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
381012
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
513115
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
KEYTRUDA (AUTHORIZED: MELANOMA)
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
NDF-RT |
N0000191260
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
||
|
NCI_THESAURUS |
C128037
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DPT0O3T46P
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
4924
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
N0000191259
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | Programmed Death Receptor-1-directed Antibody Interactions [MoA] | ||
|
DPT0O3T46P
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
m11762
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
DB09037
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
1422183-02-5
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
SUPERSEDED | |||
|
9798
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
Pembrolizumab
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
100000157957
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
1374853-91-4
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
1547545
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | RxNorm | ||
|
7499
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL2364654
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
ZZ-165
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
8257
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
Pembrolizumab
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL3137343
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
SUB167136
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY | |||
|
C106432
Created by
admin on Sat Dec 16 04:49:34 GMT 2023 , Edited by admin on Sat Dec 16 04:49:34 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_22 | 1_96 |
2_22 | 2_96 |
3_23 | 3_92 |
4_23 | 4_92 |
1_134 | 3_218 |
2_134 | 4_218 |
3_138 | 3_198 |
4_138 | 4_198 |
1_147 | 1_203 |
2_147 | 2_203 |
1_226 | 2_226 |
1_229 | 2_229 |
1_261 | 1_321 |
2_261 | 2_321 |
1_367 | 1_425 |
2_367 | 2_425 |
Glycosylation Type | MAMMALIAN |
Glycosylation Link Type | Site |
---|---|
N | 1_297 |
N | 2_297 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Molecular Formula | CHEMICAL |
|
||||
Vdss | PHARMACOKINETIC |
|
|
|||